Hepatitis C viral pathogenesis
Project Team: Qiang Liu, Q. Wu, Z. Li, M. Kandangwa
Hepatitis C virus (HCV) affects between 300,000-500,000 Canadians and 130-150 million people globally. The disease is controlled by direct-acting antivirals (DAAs) that target viral proteins. DAAs are costly and have numerous side-effects. The development of resistance is also an issue because of the error-prone nature of HCV replication. Due to these factors, the identification on novel druggable targets in the host is a top priority.
Our research is focused on identifying druggable targets through improved understanding of the molecular mechanisms regulating HCV replication and pathogenesis. This includes determining how HCV translation is regulated by viral and cellular factors. We will also target understanding the role co-infections play in HCV pathogenesis.